Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. BioStem Life Sciences
WARNING LETTER
•BioStem Life Sciences•September 15, 2023

BioStem Life Sciences – FDA Warning Letter, Sep 15, 2023

Record Details

The FDA inspected Biostem Life Sciences (Pompano Beach, FL) from September 11-15, 2023, finding significant violations of current good manufacturing practice (CGMP) requirements for their cellular products (OROPRO®, PROVISCUS®, NEOFYL®) and amniotic membrane product (RHEO®). These products, derived from human umbilical cord and amniotic membrane, are deemed drugs and biological products under the FD&C Act and PHS Act, respectively, and are also Human Cells, Tissues, or Cellular or Tissue-Based Products (HCT/Ps).

The products fail to meet HCT/P criteria for minimal manipulation and homologous use, thus requiring an approved Biologics License Application (BLA), which Biostem Life Sciences lacks.

Violations include: 1. **Inadequate environmental monitoring:** Failure to perform routine non-viable particulate monitoring and surface sampling in critical aseptic processing areas, and lack of microbiological monitoring for operator arm coverings. 2. **Unvalidated cleaning and disinfection:** Failure to validate cleaning and disinfection procedures for ISO 5 and ISO 7 cleanrooms. 3. **Inadequate production and process controls:** Manufacturing processes are not adequately validated for identity, strength, quality, and purity, with testing limited to insufficient measures. 4. **Insufficient laboratory controls:** Final product testing is limited to sterility and endotoxin, not demonstrating identity or strength.

Company
BioStem Life Sciences
Inspection date
September 15, 2023
Product type
Biologics
Office
Center for Biologics Evaluation and Research
Person
  • Melissa J. Mendoza (Director)
View Company Profile

ID · a7e95498-e152-4e44-a1c5-8519c8a02ef8

Violation Codes10
21 U.S.C. 351(a)(2)(B)FD&C Act 501(a)(2)(B)21 CFR 21021 CFR 21121 U.S.C. 331(k)21 U.S.C. 321(g)(1)21 CFR 1271.3(d)21 CFR 1271.10(a)21 CFR 1271.1521 CFR 1271.10(a)(1)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore BioStem Life Sciences
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.